Safety of recombinant human C1 esterase inhibitor for
hereditary angioedema attacks during pregnancy

J 2019

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy

MOLDOVAN, Dumitru, Jonathan A. BERNSTEIN, Roman HAKL, Grzegorz POREBSKI, Kimberly POARCH et. al.

Základní údaje

Originální název

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy

Autoři

MOLDOVAN, Dumitru (642 Rumunsko), Jonathan A. BERNSTEIN (840 Spojené státy, garant), Roman HAKL (203 Česká republika, domácí), Grzegorz POREBSKI (616 Polsko), Kimberly POARCH (642 Rumunsko), William R. LUMRY (840 Spojené státy) a Anurag RELAN (840 Spojené státy)

Vydání

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, AMSTERDAM, ELSEVIER, 2019, 2213-2198

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.574

Kód RIV

RIV/00216224:14110/19:00111741

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.jaip.2019.05.042

UT WoS

000495746100078

Klíčová slova anglicky

C1-INHIBITOR CONCENTRATE

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 1. 2020 07:45, Mgr. Tereza Miškechová

Anotace

V originále

Hereditary angioedema (HAE) is a rare (<1 in 50,000) ge-netic disorder characterized by episodes of cutaneous andmucosal angioedema. HAE is caused by insufficient suppressionof complement and contact-system cascades due to a deficiencyof functional C1 inhibitor (C1-INH). It has been demonstratedthat HAE abdominal attacks are more frequent during preg-nancy, but there is no consensus on which trimester is mostassociated with increased attack rates.Some data suggest thatmore severe attacks and symptoms occur during thefirsttrimester, whereas other data suggest a greater number of attacksin the second and third trimesters. Changes in hormone levelsduring pregnancy may exacerbate HAE attacks, and concernswith administration of certain medications during pregnancy cancomplicate HAE management.

Citovat

MOLDOVAN, Dumitru, Jonathan A. BERNSTEIN, Roman HAKL, Grzegorz POREBSKI, Kimberly POARCH, William R. LUMRY a Anurag RELAN. Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. AMSTERDAM: ELSEVIER, 2019, roč. 7, č. 8, s. 2938-2940. ISSN 2213-2198. Dostupné z: https://dx.doi.org/10.1016/j.jaip.2019.05.042.

@article{1593096,
   author = {Moldovan, Dumitru and Bernstein, Jonathan A. and Hakl, Roman and Porebski, Grzegorz and Poarch, Kimberly and Lumry, William R. and Relan, Anurag},
   article_location = {AMSTERDAM},
   article_number = {8},
   doi = {http://dx.doi.org/10.1016/j.jaip.2019.05.042},
   keywords = {C1-INHIBITOR CONCENTRATE},
   language = {eng},
   issn = {2213-2198},
   journal = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE},
   title = {Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy},
   url = {http://dx.doi.org/10.1016/j.jaip.2019.05.042},
   volume = {7},
   year = {2019}
}

TY  - JOUR
ID  - 1593096
AU  - Moldovan, Dumitru - Bernstein, Jonathan A. - Hakl, Roman - Porebski, Grzegorz - Poarch, Kimberly - Lumry, William R. - Relan, Anurag
PY  - 2019
TI  - Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy
JF  - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
VL  - 7
IS  - 8
SP  - 2938-2940
EP  - 2938-2940
PB  - ELSEVIER
SN  - 22132198
KW  - C1-INHIBITOR CONCENTRATE
UR  - http://dx.doi.org/10.1016/j.jaip.2019.05.042
L2  - http://dx.doi.org/10.1016/j.jaip.2019.05.042
N2  - Hereditary angioedema (HAE) is a rare (<1 in 50,000) ge-netic disorder characterized by episodes of cutaneous andmucosal angioedema. HAE is caused by insufficient suppressionof complement and contact-system cascades due to a deficiencyof functional C1 inhibitor (C1-INH). It has been demonstratedthat HAE abdominal attacks are more frequent during preg-nancy, but there is no consensus on which trimester is mostassociated with increased attack rates.Some data suggest thatmore severe attacks and symptoms occur during thefirsttrimester, whereas other data suggest a greater number of attacksin the second and third trimesters. Changes in hormone levelsduring pregnancy may exacerbate HAE attacks, and concernswith administration of certain medications during pregnancy cancomplicate HAE management.
ER  -

MOLDOVAN, Dumitru, Jonathan A. BERNSTEIN, Roman HAKL, Grzegorz POREBSKI, Kimberly POARCH, William R. LUMRY a Anurag RELAN. Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. \textit{JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE}. AMSTERDAM: ELSEVIER, 2019, roč.~7, č.~8, s.~2938-2940. ISSN~2213-2198. Dostupné z: https://dx.doi.org/10.1016/j.jaip.2019.05.042.

Podrobný výpis o publikaci